Ardelyx, Inc. Common Stock ARDX
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-03T21:10:57.199Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T21:10:43.966131758Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-03T21:10:55.350053+00:00
Ardelyx, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 2.51 | 144.8% | 23.3% | |||
| 25Δ | 2.64 | 129.1% | 19.5% | |||
| 30Δ | 2.78 | 113.3% | 15.6% | |||
| 35Δ | 3.42 | 95.4% | 14.8% | 2.91 | 97.6% | 11.8% |
| 40Δ | 3.34 | 103.8% | 13.9% | 3.04 | 92.5% | 9.1% |
| 45Δ | 3.26 | 112.3% | 13.0% | 3.17 | 109.9% | 8.9% |
| 50Δ | 3.18 | 120.8% | 12.1% | 3.31 | 127.2% | 8.7% |
| 55Δ | 3.09 | 129.2% | 11.2% | |||
| 60Δ | 3.01 | 137.7% | 10.3% | |||
| 65Δ | ||||||
| 70Δ | ||||||
| 75Δ | ||||||
| 80Δ | 2.29 | 517.1% | 25.8% | 6.72 | 303.1% | 5.3% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.51
- IV
- 144.8%
- B/E move
- 23.3%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.64
- IV
- 129.1%
- B/E move
- 19.5%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.78
- IV
- 113.3%
- B/E move
- 15.6%
35Δ
- Pseudo strike
- 3.42
- IV
- 95.4%
- B/E move
- 14.8%
- Pseudo strike
- 2.91
- IV
- 97.6%
- B/E move
- 11.8%
40Δ
- Pseudo strike
- 3.34
- IV
- 103.8%
- B/E move
- 13.9%
- Pseudo strike
- 3.04
- IV
- 92.5%
- B/E move
- 9.1%
45Δ
- Pseudo strike
- 3.26
- IV
- 112.3%
- B/E move
- 13.0%
- Pseudo strike
- 3.17
- IV
- 109.9%
- B/E move
- 8.9%
50Δ
- Pseudo strike
- 3.18
- IV
- 120.8%
- B/E move
- 12.1%
- Pseudo strike
- 3.31
- IV
- 127.2%
- B/E move
- 8.7%
55Δ
- Pseudo strike
- 3.09
- IV
- 129.2%
- B/E move
- 11.2%
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 3.01
- IV
- 137.7%
- B/E move
- 10.3%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 2.29
- IV
- 517.1%
- B/E move
- 25.8%
- Pseudo strike
- 6.72
- IV
- 303.1%
- B/E move
- 5.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 88.26% | |
| 97.02% | |
| 115.24% | |
| 73.89% | |
| 87.93% | |
| 193.38% | |
| 118.07% | |
| 86.88% | |
| 218.16% | |
| 162.84% | |
| 234.19% | |
| 150.91% | |
| 201.54% | |
| 187.98% | |
| 210.17% | |
| 162.65% | |
| 203.88% | |
| 161.03% | |
| 187.45% | |
| 230.83% | |
| 165.47% | |
| 222.23% |
Biotechnology
ARGX
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The…
More →ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company is headquartered in…
More →ARTV
Artiva Biotherapeutics, Inc. is a cutting-edge biotechnology firm dedicated to revolutionizing cancer therapy through its proprietary natural killer (NK) cell platform. With a…
More →ARVN
Arvinas, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of therapies to break down disease-causing proteins.…
More →ARWR
Arrowhead Pharmaceuticals, Inc. develops drugs for the treatment of intractable diseases in the United States. The company is headquartered in Pasadena, California.
More →ASMB
Assembly Biosciences, Inc. is a clinical-stage biotechnology company in the United States. The company is headquartered in South San Francisco, California.
More →